M.D. Anderson Cancer Center
The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes
To determine the rate of pathologic response (\<50% viable tumor or \>50% fibrosis) for non-metastatic sinonasal melanoma patients having surgical resection after receiving neoadjuvant combination immunotherapy followed by radiation therapy. To determine the rate of pathologic response (\<50% viable tumor or \>50% fibrosis) for non-metastatic anorectal melanoma patients receiving neoadjuvant intent combination immunotherapy followed by radiation therapy.
Inclusion Criteria For all patients * Evidence of mucosal tumor on clinical exam or imaging. * No evidence of distant metastasis * Patients must be planned for combination immunotherapy (e.g. ipilimumab and nivolumab or nivolumab and relatlimab). * ECOG performance status ≤3. * Age ≥18 years because melanoma is extremely rare in patients \<18 years of age and RT is considered high risk in this population due to risk of secondary malignancy and potentially growing tissues that may be adversely impacted by RT. * RT is a known teratogen. For this reason women of child-bearing potential and men…
Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.